Highlights

  • The FDA indicated that the HEALEY ALS Platform Trial could potentially serve as a single registrational study for NUZ-001, subject to the required evidence standard.
  • The trial design uses placebo control and clinically meaningful endpoints assessed after 36 weeks of treatment.
  • NUZ-001 remains investigational and is not approved for commercial use in any jurisdiction.
  • Regimen I enrolment is complete, with topline results expected in late Q2 2027.
  • A separate expanded access program is expected to begin in the first quarter of 2027 and provide treatment to approximately 200 US patients for up to 96 weeks.

Neurizon Therapeutics Limited (ASX:NUZ) is an Australian clinical-stage biotechnology company focused on developing investigational treatments for neurodegenerative diseases, with NUZ-001 currently being evaluated for amyotrophic lateral sclerosis (ALS). On 6 October 2026, the company reported written feedback from the US Food and Drug Administration through a Type C process, providing additional clarity on how the ongoing HEALEY ALS Platform Trial may contribute to a future New Drug Application (NDA).

FDA Feedback on the Registrational Path

According to Neurizon, the FDA indicated that the HEALEY ALS Platform Trial could potentially serve as a single registrational study supporting an NDA for NUZ-001. The company said the agency considered the placebo-controlled design, which evaluates clinically meaningful endpoints after 36 weeks of treatment, appropriate for consideration under the traditional approval pathway.

The feedback does not guarantee that the trial will be sufficient for approval. The company stated that the standard of substantial evidence must still be met and that supporting evidence would be required alongside the study results. The FDA also indicated that a strong scientific rationale would be expected if the primary endpoint were not achieved.

Role of Biomarkers and Trial Progress

The company said the FDA noted that plasma neurofilament light chain, a biomarker associated with nerve damage, could play a supporting role in the evidence package. NUZ-001 is being evaluated as Regimen I within the adaptive Phase 2/3 HEALEY ALS Platform Trial, and enrolment in that regimen is complete.

Topline results from Regimen I are expected in late Q2 2027. Until those results are available, it is not known whether the study will meet its primary endpoint or provide the level of evidence needed for a regulatory submission.

Expanded Access and Other Regulatory Steps

Neurizon also highlighted an expanded access program expected to begin in the first quarter of 2027. The program is expected to provide treatment to approximately 200 people with ALS in the United States for up to 96 weeks. NUZ-001 remains investigational, and the company has not announced a timetable for any future NDA submission.

The company also noted that a Fast Track Designation request was denied in January 2026 and that a resubmission is under evaluation. No outcome from that resubmission had been reported in the 6 October 2026 announcement.

Key Insights

The FDA feedback gives Neurizon a clearer framework for the evidence that may be required if NUZ-001 progresses toward an NDA. However, the regulatory pathway remains dependent on clinical results, supporting evidence and subsequent FDA review. The next major milestones identified by the company are the expanded access program in early 2027 and topline data from Regimen I in late Q2 2027.